5 March 2024 in IEEE Journal of Biomedical and Health Informatics
Drug repositioning greatly reduces drug development costs and time by discovering new indications for existing drugs. With the development of technology and large-scale biological databases, computational drug repositioning has increasingly attracted remarkable attention, which can narrow down repositioning candidates. Recently, graph neural networks (GNNs) have been widely used and achieved promising results in drug repositioning. However, the existing GNNs based methods usually focus on modeling the complex drug-disease association graph, but ignore the semantic information on the graph, which may lead to a lack of consistency of global topology information and local semantic information for the learned features. To alleviate the above challenge, we propose a novel drug repositioning model based on graph contrastive learning, termed DRGCL. First, we treat the known drug-disease associations as the topology graph. Second, we select the top- $K$ similar neighbor from drug/disease similarity information to construct the semantic graph rather than use the traditional data augmentation strategy, thereby maximally retaining rich semantic information. Finally, we pull closer to embedding consistency of the different embedding spaces by graph contrastive learning to enhance the topology and semantic feature on the graph. We have evaluated DRGCL on four benchmark datasets and the experiment results show that the proposed DRGCL is superior to the state-of-the-art methods. Especially, the average result of DRGCL is 11.92% higher than that of the second-best method in terms of AUPRC. The case studies further demonstrate the reliability of DRGCL. Experimental datasets and experimental codes can be found in https://github.com/Jiaxiao123/DRGCL .
26 January 2025 in Structures
8 October 2025 in IEEE Transactions on Computational Biology and Bioinformatics
Drug repositioning, a promising strategy in drug development, aims to identify new indications for existing drugs, reduce costs, and lower safety risks. Due to their unique advantages in modeling higher-order relations among nodes, hypergraphs and hypergraph neural networks (HGNN) have become increasingly popular in drug repositioning. However, most HGNN-based methods fail to account for the diverse relations generated during the convolution process and do not explicitly model high-order interactions, limiting their ability to capture high-order interaction information adequately. To address these limitations, we propose a hypergraph convolutional network with explicit high-order interaction extraction for drug repositioning, termed HGCNDR. Our model introduces a relation-aware hypergraph convolution operation to handle distinct relation types and an effective strategy using the Hadamard product to model high-order interactions among drugs and diseases, efficiently extracting the resulting high-order interaction information. Specifically, HGCNDR constructs two feature graphs and a hypergraph based on drug similarity features, disease similarity features, and drug-disease association networks. HGCNDR then employs graph convolutional networks to extract embeddings from the feature graphs, while using the relation-aware hypergraph convolution operation and the strategy to extract structural and high-order interaction information embeddings from the hypergraph. Additionally, to preserve the common semantics between the embeddings extracted from the feature graphs and the hypergraph, HGCNDR introduces a consistency constraint. The experimental results demonstrate that HGCNDR has competitive performance compared to several baseline methods. Moreover, case studies on Alzheimer's disease and Breast carcinoma confirm that HGCNDR is able to retrieve more actual drug-disease associations in the top prediction results.